Thursday
Apr192012
Can you count on the new oral anticoagulants?


Presented by Peter Loewen at the 23rd Annual Drug Therapy Decision-Making Course, Vancouver, BC. April 20, 2012.
REFERENCES from the talk
- ROCKET-AF
- RE-LY
- RE-LY Secondary Prevention
- RE-LY: Efficacy and safety of dabigatran compared with warfarin at different levels of INR control for stroke prevention in AF61194-4/abstract)
- AVERROES
- ARISTOTLE
- CCS Atrial Fib Guidelines Focused Update 201200046-3/abstract)
- CCS Atrial Fib Guidelines 2010
- ESC Task Force: New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes
- Dabigatran Association With Higher Risk of Acute Coronary Events
- Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY Trial
- Emergency Hospitalizations for Adverse Drug Events in Older Americans
- Cost-Effectiveness of Dabigatran for Stroke Prophylaxis in Atrial Fibrillation
- Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Patients With Atrial Fibrillation and Prior Stroke or TIA
- Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation
- Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses
RE-COVER: Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
- EINSTEIN: Oral Rivaroxaban for Symptomatic Venous Thromboembolism
- EINSTEIN-PE: Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism